Logotype for Alector Inc

Alector (ALEC) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Alector Inc

Q3 2026 earnings summary

5 Nov, 2026

Executive summary

  • Q3 net income was $124.6 million, primarily reflecting recognition of $162.9 million in remaining GSK deferred revenue after performance obligations ended.

  • AL050 was licensed exclusively worldwide to Genentech for $100.0 million upfront, up to $1.17 billion in milestones and tiered royalties; the ABC platform was retained.

  • Pipeline focus shifted to ABC-enabled programs after GSK programs were discontinued; no active clinical trials were reported.

Financial highlights

  • Q3 collaboration revenue was $162.9 million vs. $3.3 million YoY, primarily from recognition of remaining GSK deferred revenue.

  • Q3 operating income was $123.8 million vs. an operating loss of $37.6 million YoY; net income was $124.6 million vs. a net loss of $34.7 million.

  • Q3 R&D was $30.0 million vs. $29.4 million; G&A was $9.0 million vs. $11.5 million YoY.

  • 9M revenue was $167.2 million vs. $14.8 million; net income was $78.7 million vs. a net loss of $105.7 million.

  • 9M R&D was $67.4 million vs. $90.6 million and G&A was $25.4 million vs. $40.6 million, mainly reflecting lower personnel costs after workforce reductions.

Outlook and guidance

  • Cash, cash equivalents and investments, plus the Genentech upfront payment and October offering proceeds net of the Spur payment, are expected to fund operations into 2H 2029; estimates depend on assumptions that may change.

  • AL137 first-in-human SC dosing in Australia is targeted by April 2027, with a U.S. IND submission targeted for Q2 2027; AL164 and AL062 first-in-human studies are targeted for Q2 2028.

  • R&D spending on latozinemab and nivisnebart is expected to decline as trials wind down, while investment continues in research and preclinical programs.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Alector